Holen Sie sich die Stockscreener-App
1.50
4.46%
-0.07
Vorhandelsmarkt:
1.51
0.01
+0.67%
Schlusskurs vom Vortag:
$1.57
Offen:
$1.55
24-Stunden-Volumen:
26,637
Relative Volume:
0.27
Marktkapitalisierung:
$50.44M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-28.32M
KGV:
-0.1415
EPS:
-10.6039
Netto-Cashflow:
$-15.52M
1W Leistung:
+3.45%
1M Leistung:
-18.03%
6M Leistung:
-76.67%
1J Leistung:
-68.68%
1-Tages-Spanne:
$1.4945
$1.57
1-Wochen-Bereich:
$1.41
$1.6699
52-Wochen-Spanne:
$1.28
$9.50
Dogwood Therapeutics Inc Stock (DWTX) Company Profile
Firmenname
Dogwood Therapeutics Inc
Sektor
Branche
Telefon
(866) 620-8655
Adresse
44 MILTON AVENUE, ALPHARETTA
Compare DWTX vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DWTX
Dogwood Therapeutics Inc
|
1.50 | 52.80M | 0 | -28.32M | -15.52M | -10.60 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Dogwood Therapeutics Inc Aktie (DWTX) Neueste Nachrichten
DWTX Q1 2026 Earnings: Narrower-Than-Expected Loss Fails to Lift SharesFinal Results - newsline.com
DWTX Q1 2026 Earnings: Narrower-than-expected loss as stock slides 8.5%EBITDA Analysis - newsline.com
DWTX Q1 2026 Earnings: Narrower Loss Meets Investor Skepticism as Stock DeclinesUpward Estimate Revision - newsline.com
DWTX News | DOGWOOD THERAPEUTICS INC (NASDAQ:DWTX) - ChartMill
Dogwood Therapeutics Inc. (DWTX) Q1 2026 Earnings: Better-Than-Expected Loss Highlights Cost Discipline - newsline.com
Dogwood Therapeutics Inc. (DWTX) Rises 1.2% as Stock Holds Above Key SupportVolume Climax - newsline.com
Dogwood Therapeutics Inches Lower as Stock Tests Key Support Near $1.69Take Profit Levels - Newser
Dogwood Therapeutics Inc. (DWTX) Q1 2026 Earnings: Narrower Loss Surprises as Pre‑Revenue Biotech Focuses on Pipeline ProgressEarnings Whisper Number - newsline.com
Dogwood Therapeutics Q1 2026 Earnings: Narrower-Than-Expected Loss Amid Continued Preclinical DevelopmentEPS Growth Rate - Newser
Analysts Are Bullish on Top Healthcare Stocks: Invivyd (IVVD), Century Therapeutics (IPSC) - The Globe and Mail
PRODU - produ
DWTX Reiterated by HC Wainwright & Co. -- Price Target Maintained at $12.00 - GuruFocus
H.C. Wainwright Maintains Dogwood Therapeutics(DWTX.US) With Buy Rating, Maintains Target Price $12 - Moomoo
Dogwood launches 12-week extension study for pain drug Halneuron - Investing.com UK
Dogwood launches 12-week extension study for pain drug Halneuron By Investing.com - Investing.com Australia
Dogwood Therapeutics Announces Commencement of Halneuron® - GlobeNewswire
Chemo nerve pain patients get 12-week access to non-opioid Halneuron trial - Stock Titan
Dogwood Therapeutics, Inc. Q1 2026 SEC 10-Q Filing – Financial Statements, Management Discussion, and Risk Factors – Minichart - minichart.com.sg
Dogwood Therapeutics 1Q Rev $0.00 >DWTX - Moomoo
Armistice Capital (NASDAQ: DWTX) reports 9.99% Dogwood stake - Stock Titan
Dogwood Therapeutics 1Q 2026: Revenue $2.41M, EPS ($0.15) — 10-Q Summary - TradingView
Dogwood Therapeutics (Nasdaq: DWTX) posts Q1 2026 loss, flags cash risk - Stock Titan
Dogwood Therapeutics Announces First Quarter 2026 Financial Results - Sahm
Dogwood Therapeutics 1Q Loss $4.99M >DWTX - Moomoo
Dogwood Therapeutics Reports First Quarter 2026 Results and Progress on Pain Pipeline - citybuzz -
Dogwood Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Dogwood Therapeutics Reports Q1 2026 Results, Advances Halneuron® and SP16, and Secures $100M Antiviral Partnership 1 - Minichart
Dogwood Therapeutics (NASDAQ:DWTX) Beats EPS Estimates in Q1 2026, Phase 2b Trial on Track - ChartMill
DOGWOOD THERAPEUTICS ($DWTX) Releases Q1 2026 Earnings - Quiver Quantitative
Dogwood Therapeutics reports Q1 2026 net loss $5.0M, cash $13.2M, Halneuron Phase 2b on track - TradingView
Dogwood Therapeutics (DWTX) narrows Q1 loss and advances pain pipeline - Stock Titan
Dogwood Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Dogwood Therapeutics Q1 net loss narrows, no revenue reported - TradingView
DWTX: Pipeline advances, reduced net loss, and new partnership drive positive outlook for 2026 - TradingView
Chemo pain drug developer Dogwood lands FDA, NCI backing and $100M deal - Stock Titan
Dogwood Therapeutics : Corporate Presentation (Dogwood Therapeutics Non Confidential Corporate Update May 2026) - marketscreener.com
Dogwood Therapeutics Inc expected to post a loss of 26 cents a shareEarnings Preview - TradingView
TradingKey - TradingKey
DWTX Dogwood stock climbs 4.2% after pharmaceutical company posts massive earnings beat, EPS smashes estimates by 94%SPAC - Newser
What separates Dogwood (DWTX) from the pack? (Eye on Rally) 2026-05-08Pre Earnings - Newser
Dogwood Therapeutics to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026 - The Manila Times
Analysts Offer Insights on Healthcare Companies: Dogwood Therapeutics (DWTX), NRX Pharmaceuticals (NRXP) and Immuneering (IMRX) - The Globe and Mail
[ARS] Dogwood Therapeutics, Inc. SEC Filing - Stock Titan
Big capital authorization vote ahead for Dogwood Therapeutics (NASDAQ: DWTX) - Stock Titan
Dogwood Therapeutics files to sell 28.04M shares of common stock for holders - MSN
Dogwood licenses IMC-1, IMC-2 antiviral assets to PRIDCor By Investing.com - Investing.com Canada
Dogwood licenses IMC-1, IMC-2 antiviral assets to PRIDCor - Investing.com
Dogwood Therapeutics Announces Worldwide Development and - GlobeNewswire
DWTX (Dogwood Therapeutics Inc.) posts far narrower Q4 2025 loss than consensus estimates, yet shares dip 4.47% today.Momentum Score - Cổng thông tin điện tử Tỉnh Sơn La
Finanzdaten der Dogwood Therapeutics Inc-Aktie (DWTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.27%
1.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):